Amgen Scores Key Survival Win with IMDELLTRA Lung Cancer Trial
Amgen's (NasdaqGS:AMGN) Phase 3 trial for IMDELLTRA in first-line maintenance extensive stage small cell lung cancer has yielded positive results, with a survival benefit reported.
The study, known as DeLLphi-305, is notable as the first Phase 3 trial to demonstrate an overall survival benefit for a BiTE therapy in this setting. This milestone is seen as significant for Amgen's oncology franchise and treatment options in small cell lung cancer.
The positive outcome of the DeLLphi-305 study adds context to Amgen's fundamentals and risk profile, with some analysts viewing it as a key catalyst for the company's future growth prospects. However, investors are cautioned that commercial execution will still be a crucial factor in determining the practical contribution of IMDELLTRA.
The DeLLphi-305 result reinforces Amgen's narrative around high-margin, targeted therapies supporting long-term revenue and earnings. The trial's success also ties into the company's late-stage oncology pipeline, which analysts see as a key driver alongside cardiometabolic and biosimilar opportunities.